which company owns retatrutide Significantly Reduces Visceral Fat in Clinical Trials Retatrutide for Weight Loss: TRIUMPH-1

LiuWZhangLXuHJLiYHuCMYangJYet al

The researchers found that 137 patients (47.6%) discontinued their medication due to cost or insurance-related issues, 42 (14.6%) due to side effects, 34 (11.8%) due to shortages, 7 (2.4%) due to switching to a compounded medication, and 5 (1.7%) due to unsatisfactory weight loss

de Bree A, Verschuren WM, Blom HJ, Kromhout D

Retatrutide could be more efficacious than tirzepatide for the treatment of T2DM and obesity

Methods Search Strategy and Study Selection The Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist was inspected for the systematic review ( Tables S1, S2 , respectively